0000950170-24-014066.txt : 20240212
0000950170-24-014066.hdr.sgml : 20240212
20240212195108
ACCESSION NUMBER: 0000950170-24-014066
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240208
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Maltbie Shane
CENTRAL INDEX KEY: 0001786301
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41365
FILM NUMBER: 24622141
MAIL ADDRESS:
STREET 1: C/O AXCELLA HEALTH INC.
STREET 2: 840 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HilleVax, Inc.
CENTRAL INDEX KEY: 0001888012
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 HARRISON AVE, SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02118
BUSINESS PHONE: (617) 213-5054
MAIL ADDRESS:
STREET 1: 321 HARRISON AVE, SUITE 500
CITY: BOSTON
STATE: MA
ZIP: 02118
4
1
ownership.xml
4
X0508
4
2024-02-08
0001888012
HilleVax, Inc.
HLVX
0001786301
Maltbie Shane
C/O HILLEVAX, INC.,
321 HARRISON AVE, SUITE 500
BOSTON
MA
02118
false
true
false
false
Chief Financial Officer
false
Common Stock
2024-02-08
4
S
false
3576
14.9315
D
40656
D
Common Stock
2024-02-08
4
A
false
47522
0.00
A
88178
D
Stock Option (Right to Buy)
15.06
2024-02-08
4
A
false
61894
0.00
A
2034-02-07
Common Stock
61894
61894
D
Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units ("RSUs"), which sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
The price reported in Column 4 is a weighted average price calculated by the broker executing the sell-to-cover transactions. These shares were sold as part of a block trade in multiple transactions, and the Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate sales price.
Represents RSUs which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 8, 2024, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
The option is exercisable as it vests. The option will vest with respect to 25% of the shares of common stock on February 8, 2025 and will vest with respect to the remaining shares in equal monthly installments over the following three years subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.
/s/ Paul Bavier, Attorney-in-Fact for Shane Maltbie
2024-02-12